

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
APPLICATION

Inventor(s): BOUCHARD et al.

Appln. No.: 08 786,937

Series Code ↑

Serial No. ↑

Group Art Unit

1654

Examiner:

Delaëroix-Muirhead

Atty. Dkt.

PMS

235299

960018PH/De

M#

Client Ref

Filed: January 22, 1997

Title: LHRH-ANTAGONISTS IN THE TREATMENT

(Our Deposit Account No. 03-3975)

(Our Order No.

11468


235299

C#

M#

Date:

May 9, 2000

Asst. Commissioner of Patents
Washington, D.C. 20231

Sir:

REPLY/AMENDMENT/LETTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herein by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. "Small Entity" statement(s) filed

- ☐ previously
☐ herewith

(No.)

	Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code
2. Total Effective Claims	17	**minus 20	0	x \$18/\$9 =	+ 0	103/203
3. Independent Claims	2	***minus 3	0	x \$78/\$39 =	+ 0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)	add			+ \$260/\$130 =	+ 0	104/204
5. Original due Date: May 1, 2000	<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached	(1 mo)	\$110/\$55 =				115/215
	(2 mos)	\$380/\$190 =	+ 110			116/216
	(3 mos)	\$870/\$435 =				117/217
7. Enter any previous extension fee paid since above original due date and subtract	-					
8.	Extension Fee Attached				+ 110	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee	+ \$/\$ =				+ 0	148/248
10. If IDS attached requires Official Fee,	add + \$ =				+ 0	126
or if Rule 97(d) Petition	add + \$ =					122
11. After-Final Request Fee per rules 129(a) and 17(r)	+ \$760/380 =				+ 0	146/246
12. No. of additional inventions for examination per Rule 129(b)	x \$760/380 ea =				+ 0	149/249
13. Petition fee for					+ 0	
14.	TOTAL FEE ENCLOSED =				\$110	

15. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP
Intellectual Property Group

By Atty: Ann S. Hobbs, Ph.D.

Reg. No. 36830

1100 New York Avenue, N.W.

Ninth Floor East Tower

Washington, D.C. 20005-3918

Tel: (202) 861-3000

Atty/Sec: ASH/maf

Sig:

Fax:

(202) 822-0944

Tel:

(202) 861-3063

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re PATENT APPLICATION of

BOUCHARD, et al.

Appln. No.: 08/786,937

Filed: January 22, 1997

FOR: LHRH-ANTAGONISTS IN THE
TREATMENT OF FERTILITY DISORDERS



Att: Box AF

Group Art Unit: 1654

Examiner: Delacroix-Muirhead

#17
JRP
5/15/00

* * * * *

May 9, 2000

RESPONSE

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

RECEIVED
MAY 15 2000
TECH CENTER 1600/2990

Sir:

In response to the Official Action issued February 1, 2000, please consider
the following remarks.

REMARKS

Claims 15, 16, 18-24 and 26-33 are pending. Reconsideration is requested.

Claims 21-22 and 33 stand rejected under 35 USC § 102 as being anticipated
by Diedrich et al. This rejection is traversed for the following reasons.

Diedrich describes the following protocol:

Starting on day 2 of the menstrual cycle patients were treated with 150 IU
FSH and 150 IU LH per day. On day 5 the dose of HMG was adjusted according to
the individual reaction of the patient to the simulation, as was assessed by estradiol
values and measurement of follicular growth. 15 patients were treated with 3 mg
Cetrorelix daily s.c. and an additional five patients with 1 mg per day starting on day
7 of the menstrual cycle and continued up to induction of ovulation with 10,000 IU